Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives

Abstract

The latest edition of the WHO classification of the central nervous system was published in 2021. This review summarizes the major revisions to the classification of anterior pituitary tumors. The most important revision involves preferring the terminology of pituitary neuroendocrine tumor (PitNET), even though the terminology of pituitary adenoma (PA) still can be used according to this WHO classification compared to the previous one. Moreover, immunohistochemistry (IHC) examination of pituitary-specific transcription factors (TFs), including PIT1, TPIT, SF-1, GATA2/3, and ERα, is endorsed to determine the tumor cell lineage and to facilitate the classification of PitNET/PA subgroups. However, TF-negative IHC staining indicates PitNET/PA with no distinct cell lineages, which includes unclassified plurihormonal (PH) tumors and null cell (NC) tumors in this edition. The new WHO classification of PitNET/PA has incorporated tremendous advances in the understanding of the cytogenesis and pathogenesis of pituitary tumors. However, due to the shortcomings of the technology used in the diagnosis of PitNET/PA and the limited understanding of the tumorigenesis of PitNET/PA, the application of this new classification system in practice should be further evaluated and validated. Besides providing information for deciding the follow-up plans and adjunctive treatment after surgery, this classification system offers no additional help for neurosurgeons in clinical practice, especially in determining the treatment strategies. Therefore, it is necessary for neurosurgeons to establish a comprehensive pituitary classification system for PitNET/PA that incorporates neuroimaging grading data or direct observation of invasiveness during operation or the predictor of prognosis, as well as pathological diagnosis, thereby distinguishing the invasiveness of the tumor and facilitating neurosurgeons to decide on the treatment strategies and follow-up plans as well as adjunctive treatment after surgery.

Keywords

WHO pathological classification / pituitary adenoma / PitNET / tumor classification

References

[1] WHO Classification of Tumours Editorial Board. Pituitary adenoma/pituitary neuroendocrine tumour. WHO Classification of Tumours: Central Nervous System Tumours, 2021, Lyon, IARC: 406-415

[2] AsaSL, MeteO, PerryA, et al.. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol, 2022, 33(1): 6-26

[3] MeteO, LopesMB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol, 2017, 28(3): 228-243

[4] AsaSL, Casar-BorotaO, ChansonP, et al.. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer, 2017, 24(4): C5-C8

[5] AsaSL, MeteO, CusimanoMD, et al.. Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol, 2021, 34(9): 1634-1650

[6] NgS, MessererM, EngelhardtJ, et al.. Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. Acta Neurochir (Wien), 2021, 163(11): 3131-3142

[7] RindiG, KlimstraDS, Abedi-ArdekaniB, et al.. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol, 2018, 31(12): 1770-1786

[8] HoKKY, FleseriuM, WassJ, et al.. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement. Pituitary, 2019, 22(6): 569-573

[9] HoK, FleseriuM, KaiserU, et al.. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. J Endocr Soc, 2021, 5(3): bvaa205

[10] HoKKY, GadelhaM, KaiserUB, et al.. The NETting of pituitary adenoma: a gland illusion. Pituitary, 2022, 25(3): 349-351

[11] WanX, YanZ, TanZ, et al.. MicroRNAs in Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology, 2022, 112(5): 417-426

[12] TrouillasJ, Jaffrain-ReaML, VasiljevicA, et al.. How to Classify the Pituitary Neuroendocrine Tumors (PitNET) s in 2020. Cancers (Basel), 2020, 12(2): 514

[13] MouchtourisN, SmitRD, PiperK, et al.. A review of multiomics platforms in pituitary adenoma pathogenesis. Front Biosci (Landmark Ed), 2022, 27(3): 77

[14] TurchiniJ, SiosonL, ClarksonA, et al.. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors. Endocr Pathol, 2020, 31(2): 150-155

[15] NishiokaH, InoshitaN. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol, 2018, 35(2): 57-61

[16] AsaSL. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors. Endocr Pathol, 2021, 32(2): 222-227

[17] Garcia-MartinezA, SottileJ, FajardoC, et al.. Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?. PLoS One, 2018, 13(7): e0198877

[18] RojoMG, BuenoG, SlodkowskaJ. Review of imaging solutions for integrated quantitative immunohistochemistry in the Pathology daily practice. Folia Histochem Cytobiol, 2009, 47(3): 349-354

[19] Torregrosa-QuesadaME, Garcia-MartinezA, Silva-OrtegaS, et al.. How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?. Cancers (Basel), 2019, 11(12): 1990

[20] Sanchez-TejadaL, Sanchez-OrtigaR, LamasC, et al.. Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. PLoS One, 2017, 12(7): e0180039

[21] McDonaldWC, BanerjiN, McDonaldKN, et al.. Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma. Arch Pathol Lab Med, 2017, 141(1): 104-112

[22] NeouM, VillaC, ArmignaccoR, et al.. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell, 2020, 37(1): 123-134

[23] SjostedtE, BollerslevJ, MulderJ, et al.. A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol, 2017, 134(4): 675-677

[24] VillaC, VasiljevicA, Jaffrain-ReaML, et al.. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch, 2019, 475(6): 687-692

[25] ShiR, WanX, YanZ, et al.. Clinicopathological Characteristics of Plurihormonal Pituitary Adenoma. Front Surg, 2022, 9: 826720

[26] FahlbuschR, BusleiR. The WHO classification of pituitary tumours: a combined neurosurgical and neuropathological view. Acta Neuropathol, 2006, 111(1): 86-87

[27] KnospE, SteinerE, KitzK, et al.. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery, 1993, 33(4): 610-617discussion 617–618

[28] LvL, ZhangB, WangM, et al.. Invasive pituitary adenomas with gross total resection: The wait-and-see policy during postoperative management. J Clin Neurosci, 2018, 58: 49-55

[29] LuL, WanX, XuY, et al.. Classifying Pituitary Adenoma Invasiveness Based on Radiological, Surgical and Histological Features: A Retrospective Assessment of 903 Cases. J Clin Med, 2022, 11(9): 2464

[30] BerkmannS, LattmannJ, SchuetzP, et al.. The Shape grading system: a classification for growth patterns of pituitary adenomas. Acta Neurochir (Wien), 2021, 163(11): 3181-3189

[31] MooneyMA, SarrisCE, ZhouJJ, et al.. Proposal and Validation of a Simple Grading Scale (TRANSSPHER Grade) for Predicting Gross Total Resection of Nonfunctioning Pituitary Macroadenomas After Transsphenoidal Surgery. Oper Neurosurg (Hagerstown), 2019, 17(5): 460-469

[32] BuchfelderM, FahlbuschR, AdamsEF, et al.. Proliferation parameters for pituitary adenomas. Acta Neurochir Suppl, 1996, 65: 18-21

[33] LiC, ZhuH, ZongX, et al.. Experience of trans-nasal endoscopic surgery for pituitary tumors in a single center in China: Surgical results in a cohort of 2032 patients, operated between 2006 and 2018. Clin Neurol Neurosurg, 2020, 197: 106176

[34] ZhuH, GuoJ, ShenY, et al.. Functions and Mechanisms of Tumor Necrosis Factor-alpha and Noncoding RNAs in Bone-Invasive Pituitary Adenomas. Clin Cancer Res, 2018, 24(22): 5757-5766

[35] BuchfelderM, SchlafferSM. Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas. Rev Endocr Metab Disord, 2020, 21(2): 253-261

[36] LuL, WanX, XuY, et al.. Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions. Diagnostics (Basel), 2022, 12(4): 977

[37] NomikosP, BuchfelderM, FahlbuschR. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol, 2005, 152(3): 379-387

[38] ChangEF, ZadaG, KimS, et al.. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg, 2008, 108(4): 736-745

[39] MachadoAL, NomikosP, KiesewetterF, et al.. DNA-flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis. J Endocrinol Invest, 2005, 28(9): 795-801

[40] FahlbuschR, BuchfelderM. Current Management of Invasive Pituitary Adenomas. Contemp Neurosurg, 1989, 11(17): 1-6

[41] BuchfelderM, FahlbuschR, AdamsEF, et al.. Growth Characteristics and Proliferation Parameters of Invasive Pituitary Adenomas. Adv Neurosurg, 1992, 20: 381-386

[42] LeiT, XueD, AdamsEF, et al.. Relationship between invasiveness of pituitary somatotrophinomas and structural abnormalities of protein kinase C gene in human. J Tongji Med Univ, 1997, 17(2): 68-71